Mikkelsen SU, et al. - Researchers assessed the preliminary outcomes of combination therapy (CT) with pegylated interferon-α2 and ruxolitinib in myeloproliferative neoplasms (MPN) patients (32 with polycythemia vera [PV]; 18 with low-/intermediate-1-risk myelofibrosis [MF]), the majority being resistant and/or intolerant to interferon-α2 monotherapy. They focused on remission (2013 revised criteria encompassing histologic, hematologic, and clinical responses), complete hematologic response (CHR), molecular response, and toxicity. Patients were followed for 12 months. Based on the findings, they concluded that in patients with low-/intermediate-1-risk MF and, to a lesser extent, in patients with PV, CT with interferon-α2 and ruxolitinib was efficacious.